NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $10.58 -0.06 (-0.56%) (As of 05:26 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About Artiva Biotherapeutics Stock (NASDAQ:ARTV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Artiva Biotherapeutics alerts:Sign Up Key Stats Today's Range$10.44▼$10.9050-Day Range$9.97▼$14.4752-Week Range$9.68▼$17.31Volume36,709 shsAverage Volume117,709 shsMarket Capitalization$256.98 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company OverviewArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Read More… Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTV Stock News HeadlinesHC Wainwright Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV)December 30 at 7:48 AM | americanbankingnews.comFDA ARMAT status for Affimed and Artiva’s lymphoma combo therapyDecember 6, 2024 | msn.comKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. December 30, 2024 | Porter & Company (Ad)Artiva Biotherapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | tipranks.comArtiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial StabilityNovember 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 12, 2024 | globenewswire.comArtiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 11, 2024 | globenewswire.comSee More Headlines ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $11.77 at the beginning of the year. Since then, ARTV stock has decreased by 10.1% and is now trading at $10.58. View the best growth stocks for 2024 here. How were Artiva Biotherapeutics' earnings last quarter? Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its earnings results on Tuesday, November, 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.24. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering (IPO) on Friday, July 19th 2024. The company issued 13,920,000 shares at $12.00 per share. When does Artiva Biotherapeutics' lock-up period expire? Artiva Biotherapeutics' lock-up period expires on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Artiva Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI). Company Calendar Last Earnings11/12/2024Today12/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CUSIPN/A CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$23.00 Low Stock Price Target$18.00 Potential Upside/Downside+98.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.33 Quick Ratio11.33 Sales & Book Value Annual Sales$2.60 million Price / Sales98.80 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares24,289,000Free FloatN/AMarket Cap$256.98 million OptionableN/A BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ARTV) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
